Ultomiris approved in US in IgAN

Ultomiris wins accelerated US approval for IgAN, showing 43.4% proteinuria reduction at 34 weeks.

What the company is saying

AstraZeneca PLC, via its rare disease division Alexion, is announcing that Ultomiris (ravulizumab) has received accelerated approval in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. The company frames this as the first and only C5 complement inhibitor approved for this indication, emphasizing the unmet medical need and the strength of interim clinical data. The announcement highlights a 43.4% reduction in proteinuria versus placebo at 34 weeks, based on the I CAN Phase III trial, and stresses the rapid and sustained effect. AstraZeneca is clear that continued approval is contingent on future data from the ongoing trial, specifically the primary endpoint of change in estimated glomerular filtration rate (eGFR) at week 106. The company also notes that regulatory submissions are under review in Japan and other countries, and that Ultomiris is already approved for multiple other rare diseases globally. Executive comments from Marc Dunoyer (CEO, Alexion), Richard Lafayette, MD (Stanford), and Bonnie Schneider (IgA Nephropathy Foundation) reinforce the clinical and patient impact narrative, with a confident but measured tone.

What the data suggests

The I CAN Phase III trial interim analysis shows Ultomiris achieved a 46.6% reduction in 24-hour urine protein creatinine ratio (UPCR) from baseline at week 34 (95% CI: 39.0%, 53.2%), compared to 5.6% (95% CI: -4.9%, 15.0%) for placebo, resulting in a placebo-adjusted treatment effect of 43.4% (95% CI: 33.5%, 51.8%; p<0.0001). Proteinuria reduction was seen as early as week 10 (36.7% [95% CI: 30.2%, 42.6%]) and sustained through week 34, while placebo showed only 8.5% reduction (95% CI: 0.5%, 15.8%). The safety profile was consistent with prior Ultomiris data, with the most common adverse events being upper respiratory tract infection (11.3%), nasopharyngitis (9.2%), and infusion-related reactions (8.4%) for Ultomiris, and upper respiratory tract infection (10.2%), nasopharyngitis (9.0%), and hypertension (6.6%) for placebo. The trial enrolled about 510 participants from 28 countries. IgAN affects over 200,000 people in the US, and about half of those with high proteinuria or reduced kidney function are at high risk of kidney failure within 10 years. No financial, revenue, or commercial uptake data are disclosed. The approval is based solely on proteinuria reduction; confirmation of clinical benefit on kidney function (eGFR) is still pending.

Analysis

The announcement is upbeat, highlighting accelerated US approval for Ultomiris in IgAN and strong interim clinical results (43.4% reduction in proteinuria at 34 weeks). However, the approval is conditional: continued approval depends on future verification of clinical benefit (eGFR at week 106), and the primary endpoint data will not be available for at least another year and a half. Several claims are forward-looking, including ongoing regulatory reviews in other countries and the need for further data to secure traditional FDA approval. No financial, revenue, or profitability metrics are disclosed, so the true_signal cannot exceed weak_positive. The language is optimistic but largely proportionate to the clinical milestone, though it does not address commercial uptake, pricing, or financial impact. The gap lies in the forward emphasis on future regulatory and clinical milestones, with no immediate earnings or commercial data.

Risk flags

• ●Regulatory risk remains significant: continued US approval for this indication is contingent on verification of clinical benefit in the ongoing I CAN Phase III trial, specifically the change in eGFR at week 106. If the final data do not confirm benefit, approval could be withdrawn.
• ●Commercial uptake risk is unquantified: the announcement discloses no sales, pricing, or market penetration data for Ultomiris in IgAN, leaving the financial impact and adoption rate uncertain.
• ●Safety profile appears consistent with prior use, but long-term safety in this new population is not fully established. The most common adverse events were mild to moderate, but rare or late-emerging risks cannot be ruled out until longer-term data are available.
• ●International regulatory risk exists: submissions are under review in Japan and other countries, but there is no detail on timing, likelihood of approval, or potential regional differences in regulatory requirements.

Bottom line

AstraZeneca's Ultomiris has secured accelerated US approval for IgAN based on robust interim data showing a 43.4% reduction in proteinuria at 34 weeks, addressing a substantial unmet need in a disease affecting over 200,000 Americans. The approval is conditional, with continued US market access dependent on future confirmation of kidney function benefit (eGFR) from the ongoing I CAN Phase III trial, whose primary endpoint will not read out for at least another year. The clinical data are strong for proteinuria reduction, and the safety profile is consistent with previous experience, but no financial, revenue, or commercial adoption figures are provided. International expansion is possible, with regulatory submissions pending in Japan and other countries, but timelines and approval probabilities are unclear. Investors should view this as a meaningful clinical and regulatory milestone, but with material execution and regulatory risks ahead. The most important takeaway is that while the clinical efficacy signal is compelling, the true commercial and long-term regulatory value will only be clear after final trial data and broader market uptake are established.

Announcement summary

(LSE:AZN) AstraZeneca PLC announced that Ultomiris (ravulizumab), developed by Alexion, AstraZeneca Rare Disease, has received accelerated approval in the United States to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. The approval is based on results from the I CAN Phase III trial, where Ultomiris demonstrated a 43.4% reduction in proteinuria versus placebo at 34 weeks. The I CAN Phase III trial is ongoing and will assess the primary endpoint of change from baseline in estimated glomerular filtration rate (eGFR) at week 106, with data intended to support traditional FDA approval. Ultomiris is administered intravenously every eight weeks in adults, following a loading dose. The trial enrolled approximately 510 participants from 28 countries across North America, South America, Europe, Asia, and Australia. In the prespecified interim analysis, Ultomiris showed a 46.6% reduction in 24-hour urine protein creatinine ratio (UPCR) from baseline (95% CI: 39.0%, 53.2%) at week 34, compared to 5.6% (95% CI: -4.9%, 15.0%) in patients receiving placebo, resulting in a placebo-adjusted treatment effect of 43.4% (95% CI: 33.5%, 51.8%; p<0.0001). The reduction in proteinuria was rapid, observed as early as week 10 with Ultomiris (36.7% [95% CI: 30.2%, 42.6%]) and sustained through 34 weeks, compared to placebo (8.5% [95% CI: 0.5%, 15.8%]). The safety profile observed in the trial was consistent with the known profile of Ultomiris and was generally well tolerated, with no new safety concerns identified. The most common adverse events reported for Ultomiris were upper respiratory tract infection (11.3%), nasopharyngitis (9.2%), and infusion-related reactions (8.4%), while for placebo they were upper respiratory tract infection (10.2%), nasopharyngitis (9.0%), and hypertension (6.6%). Regulatory submissions based on the interim results from the I CAN trial are also under review in Japan and additional countries. Ultomiris is already approved in the US, EU, Japan, China, and other countries for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uraemic syndrome (aHUS), generalised myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). The interim results from the I CAN trial were presented at the 2026 European Renal Association Congress, and late-breaking results will be presented at the American Society of Nephrology’s Kidney Week on 23 October 2026. IgAN affects more than 200,000 people in the US. Approximately half of people with IgAN who have elevated protein levels in urine or reduced kidney function are at high risk of progression to end-stage kidney disease (ESKD) within 10 years of diagnosis. Richard Lafayette, MD, Professor of Medicine (Nephrology) at Stanford University Medical Center and external scientific committee co-chair of the I CAN trial, stated that persistent proteinuria remains a significant challenge for many people living with IgAN. Bonnie Schneider, Director & Co-Founder of the IgA Nephropathy Foundation, commented that the approval reflects the importance of continued innovation for people living with IgAN. Marc Dunoyer, Chief Executive Officer of Alexion, said this approval marks the fifth indication for Ultomiris.

Disagree with this article?